Free Trial

The Ensign Group (ENSG) Competitors

$120.16
+1.66 (+1.40%)
(As of 05/24/2024 ET)

ENSG vs. PACS, ACHC, HQY, ITCI, BPMC, JAZZ, EXEL, STVN, ASND, and RVMD

Should you be buying The Ensign Group stock or one of its competitors? The main competitors of The Ensign Group include PACS Group (PACS), Acadia Healthcare (ACHC), HealthEquity (HQY), Intra-Cellular Therapies (ITCI), Blueprint Medicines (BPMC), Jazz Pharmaceuticals (JAZZ), Exelixis (EXEL), Stevanato Group (STVN), Ascendis Pharma A/S (ASND), and Revolution Medicines (RVMD). These companies are all part of the "medical" sector.

The Ensign Group vs.

PACS Group (NYSE:PACS) and The Ensign Group (NASDAQ:ENSG) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

96.1% of The Ensign Group shares are held by institutional investors. 3.9% of The Ensign Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

The Ensign Group received 341 more outperform votes than PACS Group when rated by MarketBeat users. However, 100.00% of users gave PACS Group an outperform vote while only 66.10% of users gave The Ensign Group an outperform vote.

CompanyUnderperformOutperform
PACS GroupOutperform Votes
10
100.00%
Underperform Votes
No Votes
The Ensign GroupOutperform Votes
351
66.10%
Underperform Votes
180
33.90%

PACS Group currently has a consensus price target of $31.00, indicating a potential upside of 7.04%. The Ensign Group has a consensus price target of $124.60, indicating a potential upside of 4.53%. Given The Ensign Group's stronger consensus rating and higher probable upside, research analysts clearly believe PACS Group is more favorable than The Ensign Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PACS Group
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00
The Ensign Group
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

The Ensign Group has higher revenue and earnings than PACS Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PACS GroupN/AN/AN/AN/AN/A
The Ensign Group$3.73B1.82$209.40M$3.8031.36

In the previous week, PACS Group had 10 more articles in the media than The Ensign Group. MarketBeat recorded 23 mentions for PACS Group and 13 mentions for The Ensign Group. PACS Group's average media sentiment score of 1.08 beat The Ensign Group's score of 0.24 indicating that The Ensign Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PACS Group
5 Very Positive mention(s)
5 Positive mention(s)
12 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
The Ensign Group
8 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

The Ensign Group has a net margin of 5.67% compared to The Ensign Group's net margin of 0.00%. PACS Group's return on equity of 17.60% beat The Ensign Group's return on equity.

Company Net Margins Return on Equity Return on Assets
PACS GroupN/A N/A N/A
The Ensign Group 5.67%17.60%6.33%

Summary

The Ensign Group beats PACS Group on 8 of the 13 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENSG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENSG vs. The Competition

MetricThe Ensign GroupSkilled nursing care facilities IndustryMedical SectorNASDAQ Exchange
Market Cap$6.78B$2.85B$5.00B$8.04B
Dividend Yield0.20%1.72%2.81%3.93%
P/E Ratio31.3618.21133.4014.97
Price / Sales1.821.172,452.2675.86
Price / Cash20.7313.3935.9531.61
Price / Book4.282.545.434.59
Net Income$209.40M$87.04M$104.34M$213.88M
7 Day Performance-0.53%0.40%-1.47%-1.35%
1 Month Performance0.43%6.81%2.64%2.90%
1 Year Performance29.76%33.68%3.36%7.54%

The Ensign Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PACS
PACS Group
1.6987 of 5 stars
$26.92
+7.3%
$30.50
+13.3%
N/A$4.04BN/A0.0032,433Quiet Period Expiration
ACHC
Acadia Healthcare
4.7421 of 5 stars
$71.32
-0.5%
$88.89
+24.6%
-6.9%$6.62B$2.93B-509.3923,500Analyst Downgrade
HQY
HealthEquity
3.9721 of 5 stars
$76.82
-0.7%
$96.17
+25.2%
+40.4%$6.59B$999.59M120.033,150Positive News
ITCI
Intra-Cellular Therapies
4.6882 of 5 stars
$65.71
-0.9%
$90.17
+37.2%
+7.3%$6.94B$464.37M-56.65610Positive News
BPMC
Blueprint Medicines
0.6735 of 5 stars
$105.46
-2.4%
$102.65
-2.7%
+75.0%$6.45B$249.38M-21.93655
JAZZ
Jazz Pharmaceuticals
4.9693 of 5 stars
$112.01
-1.0%
$192.75
+72.1%
-20.3%$7.06B$3.83B23.092,800Positive News
EXEL
Exelixis
4.9867 of 5 stars
$20.99
-1.3%
$26.13
+24.5%
+5.6%$6.36B$1.83B32.801,310Insider Selling
STVN
Stevanato Group
0 of 5 stars
€21.34
-5.5%
N/A-26.9%$6.31B$1.09B38.805,635High Trading Volume
ASND
Ascendis Pharma A/S
1.0791 of 5 stars
$124.82
-5.5%
$173.88
+39.3%
+43.5%$7.27B$288.08M-12.99879Analyst Upgrade
High Trading Volume
RVMD
Revolution Medicines
3.8141 of 5 stars
$37.38
+0.6%
$43.20
+15.6%
+44.0%$6.13B$4.57M-9.97378Positive News

Related Companies and Tools

This page (NASDAQ:ENSG) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners